TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has officially launched its Prescribers Portal for medical practitioners with prescribing power to learn more about MDMA, its effects, and the potential ability to access the molecule for their patients.

多伦多，2024年5月3日（环球通讯社）--PharmAla Biotech Holdings Inc.（以下简称“PharmAla”或“公司”）（CSE:MDMA）（OTC:MDXXF）是一家专注于研究，开发和制造LaNeo™MDMA和MDMA新型衍生物（MDXX类分子）的生物技术公司，它很高兴地宣布，它已经正式推出了其处方门户网站，供具有处方能力的医生了解更多有关MDMA的信息，其作用以及为患者获取分子的潜在能力。

The portal, which is currently live at http://sap.pharmala.ca, is available only to pre-approved medical professionals. “With the upcoming review of MDMA for the treatment of PTSD by the US Food and Drug Administration, and with increasing insurance coverage in Canada for treatments based on psychedelic molecules, we believe it is important for medical practitioners to have access to high quality educational resources regarding MDMA, its effects, and its potential use for patients with Post-Traumatic Stress Disorder,” said Nicholas Kadysh, CEO, PharmAla Biotech.

门户网站，目前位于http://sap.pharmala.ca，仅适用于预先批准的医疗专业人员。PharmAla Biotech首席执行官尼古拉斯·卡迪什（NicholasKadysh）表示：“随着美国食品和药物管理局（FDA）即将对MDMA治疗创伤后应激障碍（PTSD）的评估，以及加拿大基于迷幻分子的治疗保险覆盖率的提高，我们认为医生获得有关MDMA及其效果及其对创伤后应激障碍患者的潜在用途的高质量教育资源非常重要。”。

“As the research and regulatory environment regarding MDMA has moved quickly, most psychiatrists and medical practitioners are seeking information on clinical use and the regulatory pathways for MDMA access available in Canada. We hope our Prescribers Portal will meet this need.” PharmAla’s Prescriber Portal will host tools and resources that assist medical practitioners in treating their patients.

“随着有关MDMA的研究和监管环境的迅速发展，大多数精神科医生和医生正在寻求有关加拿大MDMA临床使用和监管途径的信息。我们希望我们的处方门户能够满足这一需求。”PharmAla的处方门户将托管有助于医生治疗患者的工具和资源。

The Company also is working towards the creation of an accredited training and Continuing Education module for physicians in both Canada and Australia, which summarizes technical information pertaining to the clinical use of MDMA. PharmAla will be hosting a webinar for medical practitioners on Wednesday, May 15th .

该公司还致力于为加拿大和澳大利亚的医生创建一个经认可的培训和继续教育模块，该模块总结了与MDMA临床使用有关的技术信息。PharmAla将于5月15日（星期三）为医生举办网络研讨会。